Abstract
We compared acute toxicity, drug exposure, in-hospital mortality, and inpatient length of stay between two currently recommended dosing protocols (from the National Comprehensive Cancer Network Guidelines) of high-dose interleukin-2 (IL-2) treatment for patients with metastatic melanoma. Patients with metastatic melanoma who received high-dose IL-2 treatment between 2003 and 2010 were identified. Chemotherapy orders, electronic medical records, paper medical charts, and patient discharge summaries were reviewed retrospectively. We identified 13 patients who had received 600,000 units/kilogram (kg)/dose and 15 patients who had received 720,000 units/kg/dose. Patients in the 720,000 units/kg/dose group had a higher rate of grade 3 and 4 bilirubin elevations (34 vs. 12 %), weight gain (any grade, 96 vs. 89 %), and thrombocytopenia (any grade, 75 vs. 65 %). Patients receiving the higher dose also experienced more dose-limiting neurotoxicity (45 vs. 23 %), large-volume diarrhea (15 vs. 0 %), and hepatotoxicity (7 vs. 0 %). There was no in-hospital mortality during treatment in either group. The average length of stay was similar between both groups (5 days, SD = 1 for both groups), and the median cumulative IL-2 exposure was similar between both groups for the first course (10.1 vs.10.5 million units/kg) and for all courses (approximately 11–12 million units/kg). Both high-dose IL-2 protocols had comparable in-hospital mortality and cumulative IL-2 exposure. The 720,000 units/kg/dose dosing scheme did not shorten the length of stay but did lead to greater acute toxicity. Therefore, as a result, we recommend 600,000 units/kg/dose when deciding between the two regimens.
Similar content being viewed by others
References
NCCN Clinical Practice Guidelines in Oncology (2013) Melanoma. Version 2.2013. http://nccn.org. Accessed 6 February
American Cancer Society (2013) Melanoma skin cancer. http://www.cancer.org/Cancer/SkinCancer-Melanoma/DetailedGuide/index. Accessed 6 February
DeVita VT, Lawrence TS, Rosenberg SA and DePinho RA (2008) Cutaneous melanoma. In: DeVita V, Lawrence T, and Rosenberg S (eds) Cancer: principles and practice of oncology, 8th edn. Lippincott Williams and Wilkins, Philadelphia, pp 1897–1951
Miller AJ, Mihm MC Jr (2006) Mechanisms of disease: melanoma. N Engl J Med 355:51–65
Atkins MB, Lotze MT, Dutcher JP et al (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105–2116
Smith FO, Downey SG, Klapper JA et al (2008) Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 14:5610–5618
Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516
Eton O, Legha SS, Bedikian AY et al (2002) Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20:2045–2052
Bedikian AY, Johnson MM, Warneke CL et al (2008) Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. J Immunotoxicol 5:201–207
Atkins MB, Hsu J, Lee S et al (2008) Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 26:5748–5754
Middleton MR, Grob JJ, Aaronson N et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158–166
Amaravadi RK, Flaherty KT (2007) Targeted therapy for metastatic melanoma. Clin Adv Hematol Oncol 5:386–393
Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 23:488–496
Aldesleukin (Proleukin) package insert (2009) Novartis Pharmaceuticals Corporations, East Hanover, NJ
DeVita VT, Lawrence TS, Rosenberg SA and DePinho RA (2008) Interleukin therapy. In: DeVita V, Lawrence T, and Rosenberg S (eds) Cancer: principles and practice of oncology, 8th edn. Lippincott Williams and Wilkins, Philadelphia, pp 1897–1951
DeVita VT, Lawrence TS, Rosenberg SA and DePinho RA (2005) Interleukin-2. In: DeVita V, Lawrence T, and Rosenberg S (eds) Cancer: principles and practice of oncology, 7th edn. Lippincott Williams and Wilkins, Philadelphia, pp 431–438
Rosenberg SA, Yang JC, Topalian SL et al (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907–913
Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS (2007) Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced disease progression after biochemotherapy. J Clin Oncol 25:3802–3807
Schwartzentruber DJ, Lawson DH, Richards JM et al (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119–2127
Cancer Therapy Evaluation Program (2010) Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003. August 9, 2006, http://ctep.cancer.gov. Accessed 15 March
Nafcillin. Drugdex®. Thomson Micromedex. Greenwood Village, CO. http://www.thomsonhc.com/hcs/librarian. Accessed 20 June 2010
Nezos A, Msaouel P, Pissimissis N et al (2011) Methods of detection of circulating melanoma cells: a comparative overview. Cancer Treat Rev 37:284–290
Ireland A, Millward M, Pearce R, Lee M, Ziman M (2011) Genetic factors in metastatic progression of cutaneous melanoma: the future role of circulating melanoma cells in prognosis and management. Clin Exp Metastasis 28:327–336
Acquavella N, Kluger H, Rhee J et al (2008) Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. J Immunother 31:569–576
Conflict of interest
This research was not funded by any organization and the authors have no conflicts to disclose in regards to funding of this research. Additional potential conflict of interest information has been completed and submitted by each author and is attached in this submission.
Author information
Authors and Affiliations
Corresponding author
Additional information
Laura M. Alwan and Kenneth Grossmann contributed equally to this work.
Rights and permissions
About this article
Cite this article
Alwan, L.M., Grossmann, K., Sageser, D. et al. Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. Targ Oncol 9, 63–71 (2014). https://doi.org/10.1007/s11523-013-0276-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-013-0276-7